Login to Your Account



Combos next wave?

Inherit the dearth: Progress meek in type 2 diabetes but Vtv trying new mechanism

By Randy Osborne
Staff Writer

Monday, July 17, 2017

At this year’s meeting of the American Diabetes Association (ADA), a scientific summit intended to highlight the latest advances, what stood out most was the lack of them, Vtv Therapeutics Inc.’s chief scientific officer (CSO), Carmen Valcarce, told BioWorld.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription